Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | GRM5 | P41594 | 6/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.33 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | OGA | O60502 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12938272 | 0.81 | ALDH1A1 (0.57) | ALDH1A1TSHRGRM5MAPK1OR51E2 | |
| SCHEMBL8197486 | 0.81 | ALDH1A1 (0.61) | ALDH1A1TSHRGRM5MAPK1OR51E2 | |
| SCHEMBL12938269 | 0.79 | ALDH1A1 (0.59) | ALDH1A1TSHRGRM5MAPK1OR51E2 | |
| SCHEMBL167247 | 0.74 | ALDH1A1 (0.61) | ALDH1A1TSHRGRM5MAPK1PIK3CD | |
| SCHEMBL303576 | 0.73 | PIK3CD (0.67) | ALDH1A1TSHRPIK3CDPIK3CAPIK3CB | |
| SCHEMBL3587356 | 0.71 | ALDH1A1 (0.51) | ALDH1A1TSHRGRM5MAPK1PIK3CD | |
| SCHEMBL12938270 | 0.69 | GRM5 (0.50) | ALDH1A1TSHRGRM5MAPK1ATAD2 | |
| SCHEMBL4409177 | 0.69 | GRM5 (0.50) | ALDH1A1TSHRGRM5ATAD2OGA | |
| SCHEMBL2072823 | 0.69 | ATAD2 (0.68) | ALDH1A1TSHRATAD2PIK3CDPIK3CA | |
| SCHEMBL6860231 | 0.68 | ATAD2 (0.55) | ALDH1A1TSHRGRM5MAPK1ATAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053910-A1 | 2 -HETEROCYCLYLOXYBENZOYL AMINO HETEROCYCLYL COMPOUNDS AS MODULATORS OF GLUCOKINASE FOR THE TREATMENT OF TYPE 2 DIABETES | ASTRAZENECA AB (SE) | 2011-03-03 | — | — | US | disclosed |
| EP-1910350-A1 | 2 -HETEROCYCLYLOXYBENZOYL AMINO HETEROCYCLYL COMPOUNDS AS MODULATORS OF GLUCOKINASE FOR THE TREATMENT OF TYPE 2 DIABETES | AstraZeneca AB (SE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007007040-A1 | 2 -HETEROCYCLYLOXYBENZOYL AMINO HETEROCYCLYL COMPOUNDS AS MODULATORS OF GLUCOKINASE FOR THE TREATMENT OF TYPE 2 DIABETES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053910-A1 | 2 -HETEROCYCLYLOXYBENZOYL AMINO HETEROCYCLYL COMPOUNDS AS MODULATORS OF GLUCOKINASE FOR THE TREATMENT OF TYPE 2 DIABETES | GCK, GCKR, HK1 | ALDH1A1 1352/4885TSHR 2872/4885GRM5 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.